Psyence BioMed, in collaboration with Southern Star Research, has been featured on Channel 9 News Australia for our role in advancing clinical research into the use of psilocybin-assisted psychotherapy for cancer patients experiencing emotional distress.
New partnership strengthens Psyence BioMed’s global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder
Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry (“ANZCTR”), under registration number 12624000449538p. The randomized, double-blind, placebo-controlled Phase IIb study will test three doses (25mg, 10mg and 1mg) of nature-derived psilocybin in 84 patients in conjunction with psychotherapy. Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.
